69.95
전일 마감가:
$70.76
열려 있는:
$71.14
하루 거래량:
6.29M
Relative Volume:
1.24
시가총액:
$228.90B
수익:
$54.98B
순이익/손실:
$7.77B
주가수익비율:
28.09
EPS:
2.49
순현금흐름:
$9.14B
1주 성능:
-6.01%
1개월 성능:
+0.04%
6개월 성능:
+7.04%
1년 성능:
-10.96%
아스트라제네카 ADR Stock (AZN) Company Profile
명칭
Astrazeneca PLC
전화
44 20 3749 5000
주소
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
AZN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
AZN
Astrazeneca PLC
|
69.95 | 228.90B | 54.98B | 7.77B | 9.14B | 2.49 |
아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
2025-02-13 | 업그레이드 | UBS | Neutral → Buy |
2025-02-12 | 개시 | Morgan Stanley | Overweight |
2024-11-20 | 업그레이드 | UBS | Sell → Neutral |
2024-11-06 | 업그레이드 | Deutsche Bank | Sell → Hold |
2024-09-13 | 다운그레이드 | Deutsche Bank | Hold → Sell |
2024-05-30 | 개시 | Goldman | Buy |
2024-04-16 | 업그레이드 | Deutsche Bank | Sell → Hold |
2024-02-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
2024-01-23 | 개시 | Morgan Stanley | Overweight |
2024-01-16 | 재개 | UBS | Sell |
2024-01-03 | 다운그레이드 | Jefferies | Buy → Hold |
2023-12-18 | 개시 | HSBC Securities | Buy |
2023-09-25 | 업그레이드 | Jefferies | Hold → Buy |
2023-07-14 | 개시 | HSBC Securities | Buy |
2023-07-12 | 업그레이드 | UBS | Neutral → Buy |
2023-07-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2023-01-05 | 개시 | BMO Capital Markets | Outperform |
2022-09-15 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
2022-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2022-08-29 | 업그레이드 | Argus | Hold → Buy |
2022-06-14 | 다운그레이드 | UBS | Buy → Neutral |
2022-02-11 | 업그레이드 | DZ Bank | Sell → Hold |
2021-12-07 | 다운그레이드 | Jefferies | Buy → Hold |
2021-08-12 | 재개 | JP Morgan | Overweight |
2021-04-12 | 다운그레이드 | Argus | Buy → Hold |
2021-03-16 | 업그레이드 | Jefferies | Hold → Buy |
2021-02-25 | 업그레이드 | UBS | Neutral → Buy |
2021-01-15 | 개시 | Deutsche Bank | Buy |
2020-12-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2020-11-30 | 업그레이드 | UBS | Sell → Neutral |
2020-11-11 | 업그레이드 | HSBC Securities | Reduce → Hold |
2020-09-29 | 개시 | Berenberg | Buy |
2019-11-22 | 개시 | SVB Leerink | Outperform |
2019-10-25 | 업그레이드 | Liberum | Hold → Buy |
2019-04-02 | 다운그레이드 | UBS | Neutral → Sell |
2019-02-05 | 개시 | Exane BNP Paribas | Outperform |
2019-01-25 | 업그레이드 | Shore Capital | Hold → Buy |
2018-12-11 | 재개 | Jefferies | Hold |
2018-10-09 | 개시 | Guggenheim | Buy |
2018-08-16 | 다운그레이드 | Jefferies | Buy → Hold |
2018-03-19 | 업그레이드 | Jefferies | Hold → Buy |
2018-02-06 | 재확인 | Leerink Partners | Mkt Perform |
2018-02-05 | 재확인 | Bernstein | Outperform |
2018-01-18 | 재확인 | Leerink Partners | Mkt Perform |
2017-12-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
2017-10-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
2017-09-25 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
2017-09-22 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
모두보기
아스트라제네카 ADR 주식(AZN)의 최신 뉴스
AstraZeneca (NASDAQ:AZN) PLC Stock Sees Institutional Growth on Nasdaq Composite - Kalkine Media
AstraZeneca and GSK fall after Trump renews pharma tariff threat - Proactive Investors
FTSE 100 Live: Stocks drop and oil spikes as Iran 'will not surrender', AstraZeneca falls on tariff threat - Proactive Investors
FTSE 100 Live: Stocks drop into the red, AstraZeneca and GSK fall on Trump tariff threat - Proactive Investors
AstraZeneca, GSK shares down after Trump threatens drug import tariffs By Investing.com - Investing.com Nigeria
FTSE 100 Live: Stocks edge higher as UK inflation eases, AstraZeneca and GSK fall - Proactive Investors
FTSE 100 Live: Stocks open higher as UK inflation eases, AstraZeneca and GSK fall - Proactive Investors
Astrazeneca makes $5.3B drug R&D pact with CSPC - BioWorld MedTech
AstraZeneca (AZN) Faces Potential Changes in Drug Advertising Ru - GuruFocus
Levi & Korsinsky Reminds AstraZeneca PLC Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025AZN - ACCESS Newswire
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer - Insider Monkey
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
Sector Update: Health Care Stocks Slide Late Afternoon - MarketScreener
AstraZeneca Inks Up To $5.3B AI Drug Deal With Chinese Firm - Law360
FIVE AT FIVE: FTSE 100 unsettled by Israel strike; AstraZeneca strikes $3.6bn Chinese AI deal - Proactive financial news
AstraZeneca and CSPC partner on AI drug research By Investing.com - Investing.com Nigeria
AstraZeneca and CSPC partner on AI drug research - Investing.com
AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal - Pharmaceutical Technology
AstraZeneca, CSPC Pharmaceuticals Enter Research Agreement - marketscreener.com
AstraZeneca signs research agreement with China's CSPC (AZN) - Seeking Alpha
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans - BioPharma Dive
AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance - insights.citeline.com
AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 BillionAstraZeneca (NASDAQ:AZN) - Benzinga
AstraZeneca, Chinese bio firm sign $5.2B drug deal - breakingthenews.net
AstraZeneca signs $5.2bn deal to develop drugs for chronic disease with Chinese biotech - Financial Times
AstraZeneca Signs Nearly $5.3 Bln AI-enabled Research Deal With China's CSPC Pharma - Nasdaq
AstraZeneca (AZN) Enters Collaboration with CSPC for Novel Thera - GuruFocus
AstraZeneca: R&D agreement with CSPC Pharmaceuticals Group - MarketScreener
AstraZeneca bets big on AI and China with $3.6bn CSPC collaboration - Proactive financial news
AstraZeneca Enters Strategic Collaboration with CSPC Pharmaceuticals Group Limited - marketscreener.com
AstraZeneca, CSPC Ink Strategic Research Collaboration for AI-Driven Drug Discovery - marketscreener.com
The Zacks Analyst Blog Highlights Microsoft, AstraZeneca and BlackRock, Taylor Devices and Geospace Technologies - TradingView
AstraZeneca partners with CSPC in deal worth up to $5.33 billion - Investing.com Nigeria
AstraZeneca forms $5.3 billion AI drug discovery deal with CSPC - Investing.com
AstraZeneca signs AI research deal with China's CSPC for chronic diseases - MarketScreener
AstraZeneca agrees to research deal worth up to $5.22 billion with CSPC - Yahoo Finance
Astrazeneca Enters Collaboration Worth Up To $5.22 Bln With CSPC Pharmaceuticals - marketscreener.com
Top Stock Reports for Microsoft, AstraZeneca & BlackRock - Yahoo Finance
Chancery Tags AstraZeneca Unit For $180M 'Expectation' Loss - Law360
Leading bank sees AstraZeneca upside seen in hypertension drug, tempers lung cancer hopes - Proactive financial news
AstraZeneca CFO Donates Shares to Charity - TipRanks
AstraZeneca CFO donates shares to charity - Investing.com
AstraZeneca CFO donates shares to charity By Investing.com - Investing.com UK
REGAstraZeneca PLCDirector/PDMR Shareholding - TradingView
AstraZeneca (AZN): Vaccine Advisory Panel Reshuffled, Impact on Pharma Stocks | AZN Stock News - GuruFocus
UBS bullish on AstraZeneca’s baxdrostat, cautious on AVANZAR By Investing.com - Investing.com Nigeria
At a bargain-basement valuation now, is AstraZeneca’s share price impossible for me to ignore? - Yahoo
AstraZeneca (AZN) Watches CDC Vaccine Policy Developments | AZN Stock News - GuruFocus
AstraZeneca Unit Owes $180 Million-Plus in Syntimmune Case (1) - Bloomberg Law News
AstraZeneca, Lilly & J&J: Strategic Moves Powering SGLT‐2 - openPR.com
아스트라제네카 ADR (AZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):